SIMILAR PATTERNS OF AMINO ACIDS FOR 4OTW_A_DB8A1101_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 416 LYS A 430 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	0.92A	4otwA-1k2pA: 29.0	4otwA-1k2pA: 28.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	VAL A 209 LYS A 222 VAL A 249 THR A 266 TYR A 268 GLY A 272 LEU A 321 ASP A 332	None	0.87A	4otwA-1k9aA: 29.9	4otwA-1k9aA: 25.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 VAL A 275 LYS A 290 VAL A 318 GLY A 340 LEU A 389 ALA A 399	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.90A	4otwA-1opkA: 28.5	4otwA-1opkA: 24.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 VAL A 275 LYS A 290 VAL A 318 THR A 334 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-4.5A) P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	4otwA-1opkA: 28.5	4otwA-1opkA: 24.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 LYS A 623 THR A 670 TYR A 672 GLY A 676 LEU A 799	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.7A) STI A 3 (-3.2A) STI A 3 ( 4.0A) STI A 3 ( 3.8A) STI A 3 (-4.4A)	0.77A	4otwA-1t46A: 26.4	4otwA-1t46A: 29.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 LYS A 38 TYR A 86 GLY A 90 LEU A 137 ASP A 148	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.2A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A) HYM A 400 (-3.9A)	0.70A	4otwA-1zltA: 20.5	4otwA-1zltA: 22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 23 LYS A 38 VAL A 68 TYR A 86 GLY A 90 LEU A 137 ASP A 148	HYM A 400 (-4.3A) HYM A 400 (-3.2A) HYM A 400 (-4.8A) HYM A 400 (-4.7A) None HYM A 400 (-4.5A) HYM A 400 (-3.9A)	0.77A	4otwA-1zltA: 20.5	4otwA-1zltA: 22.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU X 17 VAL X 25 LYS X 39 VAL X 67 THR X 82 TYR X 84 GLY X 88 LEU X 137 ALA X 147 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-4.1A) STU X 902 (-4.6A) STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 ( 4.1A) STU X 902 (-3.6A)	0.87A	4otwA-2dq7X: 29.6	4otwA-2dq7X: 31.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 162 VAL A 170 LYS A 186 VAL A 220 LEU A 290 ALA A 319 ASP A 320	None	1.05A	4otwA-2eu9A: 20.5	4otwA-2eu9A: 22.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	10	LEU A 273 VAL A 281 LYS A 295 VAL A 323 THR A 338 TYR A 340 GLY A 344 LEU A 393 ALA A 403 ASP A 404	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.7A) None H8H A 534 (-3.1A) H8H A 534 (-4.3A) H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A) H8H A 534 (-4.2A)	0.54A	4otwA-2h8hA: 33.5	4otwA-2h8hA: 22.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 LYS A 295 VAL A 323 THR A 338 GLY A 344 LEU A 393 ALA A 403	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) None None QUE A 1 (-3.3A) QUE A 1 (-3.0A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.71A	4otwA-2hckA: 31.0	4otwA-2hckA: 25.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 LYS A 273 VAL A 301 THR A 316 GLY A 322 LEU A 371 ALA A 381	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.75A	4otwA-2hk5A: 24.7	4otwA-2hk5A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LYS A 273 VAL A 301 THR A 316 GLY A 322 LEU A 371 ALA A 381 ASP A 382	1BM A 499 (-3.8A) None 1BM A 499 (-3.2A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A) 1BM A 499 (-4.4A)	0.90A	4otwA-2hk5A: 24.7	4otwA-2hk5A: 31.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 LYS A 271 VAL A 299 THR A 315 GLY A 321 LEU A 370 ALA A 380	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.6A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.76A	4otwA-2hz0A: 29.9	4otwA-2hz0A: 36.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 VAL A 299 THR A 315 GLY A 321 LEU A 370 ALA A 380 ASP A 381	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) None GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.76A	4otwA-2hz0A: 29.9	4otwA-2hz0A: 36.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 251 VAL A 259 LYS A 273 VAL A 301 THR A 316 TYR A 318 GLY A 322 LEU A 371 ALA A 381	None None 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.7A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A)	0.91A	4otwA-2og8A: 28.3	4otwA-2og8A: 32.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 588 VAL A 596 VAL A 647 THR A 663 TYR A 665 GLY A 669 LEU A 785 VAL A 548	None	1.10A	4otwA-2ogvA: 22.5	4otwA-2ogvA: 29.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 LYS A 517 TYR A 566 GLY A 570 LEU A 633 ALA A 643	None	0.97A	4otwA-2psqA: 29.1	4otwA-2psqA: 28.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 LYS A 217 THR A 265 GLY A 271 LEU A 328 ALA A 338 ASP A 339	ADE A 488 ( 4.9A) None ADE A 488 (-4.3A) ADE A 488 ( 4.1A) ADE A 488 (-4.4A) None None	0.62A	4otwA-2qluA: 24.3	4otwA-2qluA: 24.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 VAL A 732 LYS A 751 VAL A 781 THR A 796 GLY A 802 LEU A 850 ASP A 861	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.9A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.0A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A) GW7 A 1 (-4.1A)	0.63A	4otwA-2r4bA: 36.8	4otwA-2r4bA: 56.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 90 LYS A 105 VAL A 137 TYR A 155 GLY A 159 LEU A 205 ALA A 215	None ANP A1480 (-3.4A) ANP A1480 (-4.7A) ANP A1480 ( 4.9A) None ANP A1480 ( 4.7A) ANP A1480 ( 4.1A)	0.90A	4otwA-2v55A: 18.0	4otwA-2v55A: 22.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 68 VAL A 76 LYS A 94 VAL A 125 GLY A 147 LEU A 194 ASP A 205	STU A 1 (-3.8A) None STU A 1 (-2.8A) None STU A 1 ( 3.9A) STU A 1 (-4.6A) STU A 1 ( 3.8A)	0.94A	4otwA-2z7rA: 22.5	4otwA-2z7rA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 VAL A 261 LYS A 275 VAL A 303 THR A 319 GLY A 325 LEU A 374 ALA A 384	None	0.75A	4otwA-2zv7A: 28.8	4otwA-2zv7A: 31.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 LYS A 517 TYR A 566 GLY A 570 LEU A 633 ALA A 643	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 ( 4.5A) M33 A1996 ( 4.7A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A) None	0.65A	4otwA-3b2tA: 26.8	4otwA-3b2tA: 30.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 TYR A 563 GLY A 567 LEU A 630 ALA A 640 ASP A 641	C4F A 1 ( 3.9A) None None None C4F A 1 (-4.6A) C4F A 1 (-3.6A) C4F A 1 (-4.5A)	0.79A	4otwA-3c4fA: 29.0	4otwA-3c4fA: 29.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 209 LYS A 222 VAL A 249 THR A 266 TYR A 268 GLY A 272 LEU A 321 ASP A 332	None	0.87A	4otwA-3d7uA: 25.6	4otwA-3d7uA: 32.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fe3	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 3 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 70 LYS A 85 VAL A 116 TYR A 134 GLY A 138 LEU A 185 ALA A 195	None	1.03A	4otwA-3fe3A: 18.9	4otwA-3fe3A: 27.37
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 833 VAL A 841 LYS A 861 VAL A 892 TYR A 911 GLY A 915 LEU A1029	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 (-4.0A) 8ST A2001 ( 4.7A) 8ST A2001 (-4.9A) None None	0.84A	4otwA-3hngA: 28.2	4otwA-3hngA: 26.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3kex	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	12	LEU A 696 VAL A 704 CYH A 721 LYS A 723 VAL A 753 THR A 768 TYR A 770 GLY A 774 LEU A 822 ALA A 832 ASP A 833 VAL A 836	ANP A 1 (-4.4A) ANP A 1 (-3.9A) ANP A 1 (-3.5A) ANP A 1 (-3.4A) None ANP A 1 ( 4.8A) ANP A 1 (-4.3A) ANP A 1 ( 4.9A) ANP A 1 (-4.7A) None MG A1001 ( 3.1A) None	0.49A	4otwA-3kexA: 42.2	4otwA-3kexA: 99.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdy	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B (Homo sapiens)	PF07714 (Pkinase_Tyr) PF08515 (TGF_beta_GS)	8	VAL A 218 LYS A 231 THR A 279 TYR A 281 GLY A 285 LEU A 339 ALA A 349 ASP A 350	LDN A 1 ( 4.8A) None LDN A 1 (-3.8A) LDN A 1 ( 4.8A) LDN A 1 (-3.3A) LDN A 1 (-4.5A) LDN A 1 ( 3.8A) LDN A 1 (-3.9A)	0.78A	4otwA-3mdyA: 24.7	4otwA-3mdyA: 24.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 49 VAL A 57 LYS A 72 VAL A 104 TYR A 122 GLY A 126 LEU A 173 ASP A 184	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) None None None None XFE A 351 (-4.6A) None	1.01A	4otwA-3mvjA: 21.0	4otwA-3mvjA: 23.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LYS A 229 THR A 277 TYR A 279 GLY A 283 LEU A 337 ALA A 347 ASP A 348	LDN A 600 (-4.0A) LDN A 600 (-4.0A) LDN A 600 (-4.7A) LDN A 600 (-3.3A) LDN A 600 (-4.6A) LDN A 600 ( 3.8A) None	0.73A	4otwA-3my0A: 24.6	4otwA-3my0A: 27.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 LYS A 229 THR A 277 TYR A 279 GLY A 283 LEU A 337 ALA A 347	LDN A 600 (-4.5A) LDN A 600 (-4.0A) LDN A 600 (-4.0A) LDN A 600 (-4.7A) LDN A 600 (-3.3A) LDN A 600 (-4.6A) LDN A 600 ( 3.8A)	0.68A	4otwA-3my0A: 24.6	4otwA-3my0A: 27.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 VAL A 200 LYS A 215 VAL A 247 GLY A 269 LEU A 318 ASP A 329	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-2.8A) None None AMP A 577 (-4.8A) AMP A 577 (-4.0A)	0.86A	4otwA-3nyoA: 20.5	4otwA-3nyoA: 20.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 726 VAL A 734 LYS A 753 THR A 798 GLY A 804 LEU A 852 ASP A 863	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-4.7A) 03Q A 1 (-4.1A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A) 03Q A 1 (-4.0A)	0.82A	4otwA-3pp0A: 35.3	4otwA-3pp0A: 57.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	LYS A 578 VAL A 609 THR A 625 TYR A 627 GLY A 631 LEU A 683 ASP A 694	STU A 1 (-3.5A) None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A)	0.81A	4otwA-3ppzA: 27.4	4otwA-3ppzA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	7	VAL A 565 VAL A 609 THR A 625 TYR A 627 GLY A 631 LEU A 683 ASP A 694	STU A 1 (-4.9A) None STU A 1 (-4.1A) STU A 1 (-4.4A) STU A 1 (-3.2A) STU A 1 (-4.3A) STU A 1 (-3.5A)	0.61A	4otwA-3ppzA: 27.4	4otwA-3ppzA: 31.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	LEU A 63 VAL A 71 LYS A 86 THR A 144 GLY A 150 LEU A 197 ASP A 211	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.1A) ANP A1634 (-4.6A) None ANP A1634 (-4.4A) MG A 529 (-2.2A)	1.09A	4otwA-3q5iA: 19.9	4otwA-3q5iA: 25.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 345 LYS A 368 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477	STU A 1 (-3.8A) STU A 1 (-3.1A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A)	0.79A	4otwA-3s95A: 23.6	4otwA-3s95A: 25.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3s95	LIM DOMAIN KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 345 THR A 413 TYR A 415 GLY A 419 LEU A 467 ALA A 477 ASP A 478	STU A 1 (-3.8A) STU A 1 (-3.9A) STU A 1 (-4.7A) STU A 1 (-3.6A) STU A 1 (-4.6A) STU A 1 ( 4.1A) STU A 1 ( 4.2A)	0.77A	4otwA-3s95A: 23.6	4otwA-3s95A: 25.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 423 VAL A 431 LYS A 445 VAL A 473 THR A 489 TYR A 491 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-4.5A) PP2 A 1 (-4.5A) None PP2 A 1 (-3.3A) PP2 A 1 ( 4.9A) PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.62A	4otwA-3sxsA: 29.4	4otwA-3sxsA: 31.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 LYS A 514 TYR A 563 GLY A 567 LEU A 630 ALA A 640	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-4.5A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.84A	4otwA-3tt0A: 28.8	4otwA-3tt0A: 30.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 TYR A 563 GLY A 567 LEU A 630 ALA A 640 ASP A 641	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A) 07J A 1 (-3.2A) 07J A 1 (-4.7A)	0.77A	4otwA-3tt0A: 28.8	4otwA-3tt0A: 30.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	LEU A 295 VAL A 303 LYS A 317 TYR A 365 GLY A 369 LEU A 423 ASP A 434	None	0.89A	4otwA-3ulzA: 21.6	4otwA-3ulzA: 26.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 139 VAL A 147 LYS A 162 TYR A 212 GLY A 216 LEU A 263 ALA A 273	N13 A 501 (-3.7A) N13 A 501 ( 4.7A) N13 A 501 (-2.9A) N13 A 501 (-4.4A) N13 A 501 (-3.5A) N13 A 501 (-4.5A) N13 A 501 ( 3.8A)	0.60A	4otwA-3w18A: 22.3	4otwA-3w18A: 23.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 83 VAL A 91 LYS A 106 TYR A 156 GLY A 160 LEU A 207 ALA A 217	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.3A) VX6 A 500 (-4.2A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A) VX6 A 500 ( 4.2A)	0.62A	4otwA-4af3A: 19.3	4otwA-4af3A: 23.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 91 LYS A 106 TYR A 156 GLY A 160 LEU A 208 ALA A 218 ASP A 219	None EDO A1419 (-3.3A) EDO A1420 (-4.9A) None EDO A1420 ( 4.8A) None None	0.71A	4otwA-4aw2A: 19.4	4otwA-4aw2A: 22.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c02	ACTIVIN RECEPTOR TYPE-1 (Homo sapiens)	PF00069 (Pkinase) PF08515 (TGF_beta_GS)	7	VAL A 222 LYS A 235 THR A 283 TYR A 285 GLY A 289 LEU A 343 ALA A 353	TAK A1507 (-4.7A) TAK A1507 ( 4.5A) TAK A1507 (-3.6A) TAK A1507 ( 4.6A) TAK A1507 (-3.5A) TAK A1507 (-4.7A) TAK A1507 ( 4.2A)	0.61A	4otwA-4c02A: 19.2	4otwA-4c02A: 25.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4cfh	5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1 (Rattus norvegicus)	PF00069 (Pkinase) PF16579 (AdenylateSensor)	8	LEU A 22 VAL A 30 LYS A 45 TYR A 95 GLY A 99 LEU A 146 ALA A 156 ASP A 157	STU A1550 (-4.3A) None STU A1550 (-3.6A) STU A1550 (-4.5A) STU A1550 (-3.4A) STU A1550 (-4.3A) STU A1550 ( 3.8A) STU A1550 (-3.6A)	0.99A	4otwA-4cfhA: 22.4	4otwA-4cfhA: 20.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	9	LEU A 663 VAL A 671 LYS A 686 VAL A 721 TYR A 739 GLY A 743 LEU A 789 ALA A 799 ASP A 800	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.0A) None None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A) AGS A1985 ( 3.3A)	0.91A	4otwA-4crsA: 20.2	4otwA-4crsA: 23.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eqm	PROTEIN KINASE (Staphylococcus aureus)	PF00069 (Pkinase)	7	LEU A 16 VAL A 24 LYS A 39 VAL A 71 TYR A 89 LEU A 140 ASP A 151	ANP A 300 (-4.7A) ANP A 300 ( 4.7A) ANP A 300 (-3.1A) None ANP A 300 (-4.3A) ANP A 300 (-4.7A) None	0.99A	4otwA-4eqmA: 24.4	4otwA-4eqmA: 23.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 LYS A 402 VAL A 433 GLY A 454 LEU A 501 ASP A 512	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.9A)	0.81A	4otwA-4f4pA: 27.1	4otwA-4f4pA: 32.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 855 VAL A 863 LYS A 882 VAL A 911 GLY A 935 LEU A 983 ASP A 994	IZA A2001 (-3.7A) None IZA A2001 ( 4.7A) None IZA A2001 (-3.3A) IZA A2001 ( 4.7A) IZA A2001 ( 4.5A)	0.78A	4otwA-4gl9A: 28.1	4otwA-4gl9A: 28.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 855 VAL A 863 VAL A 911 TYR A 931 GLY A 935 LEU A 983 ASP A 994	IZA A2001 (-3.7A) None None None IZA A2001 (-3.3A) IZA A2001 ( 4.7A) IZA A2001 ( 4.5A)	0.74A	4otwA-4gl9A: 28.1	4otwA-4gl9A: 28.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 828 VAL A 836 LYS A 855 VAL A 884 TYR A 904 GLY A 908 LEU A 956 ALA A 966	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.5A) None 19S A1201 (-4.7A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.77A	4otwA-4hviA: 24.7	4otwA-4hviA: 33.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 828 VAL A 836 VAL A 884 TYR A 904 GLY A 908 LEU A 956 ALA A 966 ASP A 967	19S A1201 (-3.9A) 19S A1201 (-4.4A) None 19S A1201 (-4.7A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A) 19S A1201 ( 4.1A)	0.83A	4otwA-4hviA: 24.7	4otwA-4hviA: 33.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	7	LEU A 132 VAL A 140 LYS A 158 THR A 205 GLY A 211 LEU A 259 ASP A 270	None	0.75A	4otwA-4hzsA: 24.9	4otwA-4hzsA: 36.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	9	LEU A 273 VAL A 281 LYS A 295 VAL A 323 TYR A 340 GLY A 344 LEU A 393 ALA A 403 ASP A 404	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 ( 4.7A) None 0J9 A 601 ( 4.7A) 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.5A) 0J9 A 601 (-3.1A)	0.67A	4otwA-4k11A: 33.3	4otwA-4k11A: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 478 VAL A 486 LYS A 508 TYR A 557 GLY A 561 LEU A 624 ALA A 634 ASP A 635	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-2.7A) None ACP A 801 ( 4.6A) ACP A 801 (-4.4A) None MG A 802 ( 3.0A)	0.89A	4otwA-4k33A: 27.3	4otwA-4k33A: 31.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 33 VAL A 41 LYS A 56 VAL A 83 TYR A 101 GLY A 105 LEU A 153 ALA A 163	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 403 ( 4.6A) GOL A 403 (-4.1A) GOL A 404 ( 4.9A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A) GOL A 403 ( 3.0A)	0.81A	4otwA-4lg4A: 20.4	4otwA-4lg4A: 27.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 LYS A 295 VAL A 323 TYR A 340 GLY A 344 LEU A 393 ALA A 403	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) VGG A 601 ( 4.0A) VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.2A)	0.83A	4otwA-4lggA: 28.4	4otwA-4lggA: 32.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m69	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 3 (Mus musculus)	PF00069 (Pkinase)	7	VAL A 36 LYS A 51 THR A 95 GLY A 101 LEU A 150 ALA A 160 ASP A 161	ANP A 401 (-4.5A) ANP A 401 (-2.9A) ANP A 401 (-3.8A) None ANP A 401 (-4.8A) None MG A 403 ( 3.1A)	0.64A	4otwA-4m69A: 26.9	4otwA-4m69A: 25.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 VAL A 54 LYS A 69 VAL A 99 THR A 123 GLY A 128 LEU A 180 ASP A 191	SIN A 401 ( 3.9A) None None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.85A	4otwA-4o38A: 18.4	4otwA-4o38A: 22.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 595 VAL A 603 LYS A 642 THR A 687 TYR A 689 GLY A 693 LEU A 741	2TT A1201 (-4.1A) 2TT A1201 (-4.2A) 2TT A1201 ( 4.6A) None 2TT A1201 (-4.0A) 2TT A1201 (-3.5A) 2TT A1201 (-4.1A)	0.61A	4otwA-4oliA: 27.9	4otwA-4oliA: 21.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 627 VAL A 635 VAL A 685 TYR A 703 GLY A 707 LEU A 753 ALA A 763 ASP A 764	None	0.84A	4otwA-4otdA: 16.8	4otwA-4otdA: 25.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 386 VAL A 394 LYS A 409 TYR A 460 GLY A 464 LEU A 511 ALA A 521 ASP A 522	PZW A 801 (-3.9A) PZW A 801 (-4.6A) None None None PZW A 801 (-4.8A) PZW A 801 ( 4.6A) PZW A 801 (-3.2A)	0.96A	4otwA-4q9zA: 19.9	4otwA-4q9zA: 25.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ra4	PROTEIN KINASE C (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 345 VAL A 353 LYS A 368 TYR A 419 GLY A 423 ALA A 480 ASP A 481	3KZ A 701 ( 4.1A) 3KZ A 701 (-3.9A) 3KZ A 701 ( 4.7A) None None 3KZ A 701 ( 4.8A) 3KZ A 701 (-2.9A)	1.10A	4otwA-4ra4A: 20.1	4otwA-4ra4A: 27.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	9	LEU A 14 VAL A 22 LYS A 37 VAL A 65 THR A 81 TYR A 83 GLY A 87 LEU A 136 ALA A 146	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) None None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None	0.67A	4otwA-4ueuA: 28.5	4otwA-4ueuA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 65 THR A 81 TYR A 83 GLY A 87 LEU A 136 ALA A 146 ASP A 147	None ACP A1264 (-4.5A) ACP A1264 ( 4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None None	0.92A	4otwA-4ueuA: 28.5	4otwA-4ueuA: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 40 VAL A 48 LYS A 63 VAL A 92 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-4.5A) None 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.81A	4otwA-4usfA: 17.3	4otwA-4usfA: 27.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	8	LEU A 104 VAL A 112 LYS A 127 VAL A 159 TYR A 177 GLY A 181 LEU A 228 ASP A 239	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-2.6A) None None None ATP A 501 (-4.5A) ZN A 503 (-1.9A)	1.01A	4otwA-4wb7A: 21.1	4otwA-4wb7A: 22.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 LYS A 216 VAL A 248 GLY A 270 LEU A 321 ASP A 332	ANW A 601 ( 4.0A) None None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A) None	0.92A	4otwA-4wboA: 21.0	4otwA-4wboA: 20.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	8	LEU B 267 VAL B 275 LYS B 290 VAL B 318 THR B 334 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.55A	4otwA-4xeyB: 25.7	4otwA-4xeyB: 27.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	None	1.02A	4otwA-4xi2A: 28.0	4otwA-4xi2A: 22.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 616 VAL A 624 LYS A 644 VAL A 675 TYR A 693 GLY A 697 LEU A 818	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 ( 4.0A) None P30 A1001 ( 4.4A) P30 A1001 (-3.5A) P30 A1001 (-4.3A)	0.88A	4otwA-4xufA: 23.3	4otwA-4xufA: 31.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 LYS A 430 VAL A 458 TYR A 476 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-3.7A) None 746 A 702 (-4.4A) 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.91A	4otwA-4y93A: 31.1	4otwA-4y93A: 20.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	7	LEU A 408 VAL A 416 VAL A 458 THR A 474 TYR A 476 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) None 746 A 702 (-3.7A) 746 A 702 (-4.4A) 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.66A	4otwA-4y93A: 31.1	4otwA-4y93A: 20.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 LYS A 490 THR A 539 TYR A 541 LEU A 595 ALA A 605 ASP A 606	None 4CV A 801 (-3.9A) 4CV A 801 (-2.8A) 4CV A 801 (-3.9A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A) 4CV A 801 (-3.5A)	0.96A	4otwA-4yffA: 24.7	4otwA-4yffA: 28.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 THR A 539 TYR A 541 GLY A 545 LEU A 595 ALA A 605 ASP A 606	None 4CV A 801 (-2.8A) 4CV A 801 (-3.9A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A) 4CV A 801 (-3.5A)	0.68A	4otwA-4yffA: 24.7	4otwA-4yffA: 28.85
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 LYS A 514 TYR A 563 GLY A 567 LEU A 630 ALA A 640 ASP A 641	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 ( 3.1A) 38O A1769 (-4.2A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) EDO A1766 ( 4.4A) 38O A1769 (-4.0A)	0.86A	4otwA-5a46A: 28.9	4otwA-5a46A: 30.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	8	VAL A 70 LYS A 85 VAL A 116 TYR A 134 GLY A 138 LEU A 185 ALA A 195 ASP A 196	5RC A4000 (-4.6A) 5RC A4000 (-2.8A) None 5RC A4000 (-4.5A) 5RC A4000 (-3.3A) None 5RC A4000 ( 3.9A) 5RC A4000 (-3.6A)	1.01A	4otwA-5es1A: 21.8	4otwA-5es1A: 26.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 LYS A 930 TYR A 980 GLY A 984 LEU A1030 ASP A1041	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) None 5U3 A1200 (-4.5A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A) 5U3 A1200 ( 4.9A)	0.78A	4otwA-5f1zA: 28.8	4otwA-5f1zA: 32.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 599 VAL A 607 LYS A 627 THR A 674 TYR A 676 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-4.0A) 748 A1001 (-3.2A) 748 A1001 (-4.0A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.71A	4otwA-5grnA: 24.0	4otwA-5grnA: 30.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gza	PROTEIN O-MANNOSE KINASE (Danio rerio)	PF07714 (Pkinase_Tyr)	7	VAL A 93 VAL A 133 THR A 147 TYR A 149 GLY A 153 LEU A 214 ASP A 225	ADP A 401 (-4.4A) None ADP A 401 ( 4.8A) ADP A 401 ( 4.8A) ADP A 401 ( 4.1A) ADP A 401 (-4.4A) MG A 402 ( 1.8A)	0.91A	4otwA-5gzaA: 17.2	4otwA-5gzaA: 24.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	8	LEU A 20 VAL A 28 LYS A 43 VAL A 74 GLY A 96 LEU A 143 ALA A 156 ASP A 157	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-2.7A) None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A) MG A 302 ( 3.3A)	1.03A	4otwA-5hu3A: 23.0	4otwA-5hu3A: 24.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 57 VAL A 65 VAL A 109 TYR A 132 GLY A 136 LEU A 187 ASP A 198	IDV A 401 (-3.8A) IDV A 401 (-4.6A) None IDV A 401 (-3.5A) IDV A 401 (-3.4A) IDV A 401 (-4.4A) IDV A 401 (-4.0A)	0.63A	4otwA-5i3oA: 16.3	4otwA-5i3oA: 23.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 30 LYS A 45 VAL A 74 GLY A 96 LEU A 143 ALA A 153 ASP A 154	6G2 A 901 ( 4.9A) 6G2 A 901 ( 3.9A) None 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A) 6G2 A 901 (-3.4A)	0.76A	4otwA-5j5tA: 21.2	4otwA-5j5tA: 26.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 106 LYS A 121 VAL A 153 TYR A 171 GLY A 175 LEU A 221 ALA A 231 ASP A 232	None	0.93A	4otwA-5u7qA: 18.7	4otwA-5u7qA: 23.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	8	LEU A 24 VAL A 32 LYS A 47 THR A 95 TYR A 97 GLY A 101 LEU A 153 ALA A 163	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) 9WS A 401 (-3.2A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A) 9WS A 401 ( 4.0A)	0.56A	4otwA-5w5jA: 24.2	4otwA-5w5jA: 26.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	LEU A 891 VAL A 899 LYS A 919 THR A 963 TYR A 965 GLY A 969 LEU A1017	ANP A1201 (-4.1A) ANP A1201 (-4.4A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A)	0.54A	4otwA-5wnoA: 34.6	4otwA-5wnoA: 17.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wno	RECEPTOR TYROSINE-PROTEIN KINASE LET-23 (Caenorhabditis elegans)	no annotation	7	VAL A 899 LYS A 919 THR A 963 TYR A 965 GLY A 969 LEU A1017 ASP A1028	ANP A1201 (-4.4A) ANP A1201 (-3.8A) ANP A1201 (-3.9A) ANP A1201 (-4.4A) ANP A1201 ( 4.6A) ANP A1201 (-4.7A) MG A1202 ( 3.0A)	0.73A	4otwA-5wnoA: 34.6	4otwA-5wnoA: 17.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xd6	PROTEIN KINASE SUPERFAMILY PROTEIN (Arabidopsis thaliana)	no annotation	7	VAL A 83 LYS A 97 VAL A 125 TYR A 143 GLY A 147 LEU A 206 ALA A 216	ANP A1000 (-4.1A) ANP A1000 (-2.8A) None ANP A1000 (-4.3A) None ANP A1000 (-4.5A) MG A1001 ( 4.4A)	0.58A	4otwA-5xd6A: 23.9	4otwA-5xd6A: 13.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	LEU A 33 VAL A 41 LYS A 56 TYR A 101 ALA A 163 ASP A 164 VAL A 167	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 (-2.4A) ANP A 501 ( 4.2A) None MG A 502 ( 3.1A) None	0.83A	4otwA-6ao5A: 23.4	4otwA-6ao5A: 26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	9	LEU A 33 VAL A 41 LYS A 56 VAL A 83 TYR A 101 GLY A 105 LEU A 153 ALA A 163 VAL A 167	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 (-2.4A) None ANP A 501 ( 4.2A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A) None None	0.69A	4otwA-6ao5A: 23.4	4otwA-6ao5A: 26.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 LYS A 908 VAL A 938 GLY A 962 LEU A1010 ASP A1021	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-2.8A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A) MG A1203 (-1.8A)	0.95A	4otwA-6c7yA: 28.5	4otwA-6c7yA: 13.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	7	VAL A 74 LYS A 89 VAL A 120 TYR A 138 LEU A 189 ALA A 199 ASP A 200	None	1.04A	4otwA-6c9dA: 21.1	4otwA-6c9dA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c9d	SERINE/THREONINE-PRO TEIN KINASE MARK1,SERINE/THREONI NE-PROTEIN KINASE MARK1 (Homo sapiens)	no annotation	7	VAL A 74 VAL A 120 TYR A 138 GLY A 142 LEU A 189 ALA A 199 ASP A 200	None	0.88A	4otwA-6c9dA: 21.1	4otwA-6c9dA: 13.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	7	VAL A 142 LYS A 157 VAL A 212 GLY A 236 LEU A 282 ALA A 292 ASP A 293	H1N A 501 (-4.4A) H1N A 501 (-2.8A) H1N A 501 (-4.9A) H1N A 501 (-3.6A) H1N A 501 (-4.8A) H1N A 501 ( 3.9A) H1N A 501 (-3.5A)	0.77A	4otwA-6ccfA: 23.1	4otwA-6ccfA: 18.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	LEU U 20 LYS U 44 VAL U 75 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.80A	4otwA-6fdyU: 20.6	4otwA-6fdyU: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	LEU U 20 VAL U 28 LYS U 44 VAL U 75 GLY U 97 LEU U 144 ALA U 156	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 ( 4.0A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A)	0.73A	4otwA-6fdyU: 20.6	4otwA-6fdyU: undetectable

[["4OTW_A_DB8A1101_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",7,"VAL A 416;LYS A 430;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","0.92A","4otwA-1k2pA:29.0","4otwA-1k2pA:28.44"],["4OTW_A_DB8A1101_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"VAL A 209;LYS A 222;VAL A 249;THR A 266;TYR A 268;GLY A 272;LEU A 321;ASP A 332","None","0.87A","4otwA-1k9aA:29.9","4otwA-1k9aA:25.20"],["4OTW_A_DB8A1101_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;GLY A 340;LEU A 389;ALA A 399","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.90A","4otwA-1opkA:28.5","4otwA-1opkA:24.20"],["4OTW_A_DB8A1101_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;VAL A 275;LYS A 290;VAL A 318;THR A 334;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-4.5A);P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","4otwA-1opkA:28.5","4otwA-1opkA:24.20"],["4OTW_A_DB8A1101_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;LYS A 623;THR A 670;TYR A 672;GLY A 676;LEU A 799","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.7A);STI A   3 (-3.2A);STI A   3 ( 4.0A);STI A   3 ( 3.8A);STI A   3 (-4.4A)","0.77A","4otwA-1t46A:26.4","4otwA-1t46A:29.75"],["4OTW_A_DB8A1101_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;LYS A  38;TYR A  86;GLY A  90;LEU A 137;ASP A 148","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.2A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A);HYM A 400 (-3.9A)","0.70A","4otwA-1zltA:20.5","4otwA-1zltA:22.09"],["4OTW_A_DB8A1101_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"VAL A  23;LYS A  38;VAL A  68;TYR A  86;GLY A  90;LEU A 137;ASP A 148","HYM A 400 (-4.3A);HYM A 400 (-3.2A);HYM A 400 (-4.8A);HYM A 400 (-4.7A);None;HYM A 400 (-4.5A);HYM A 400 (-3.9A)","0.77A","4otwA-1zltA:20.5","4otwA-1zltA:22.09"],["4OTW_A_DB8A1101_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",10,"LEU X  17;VAL X  25;LYS X  39;VAL X  67;THR X  82;TYR X  84;GLY X  88;LEU X 137;ALA X 147;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-4.1A);STU X 902 (-4.6A);STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 ( 4.1A);STU X 902 (-3.6A)","0.87A","4otwA-2dq7X:29.6","4otwA-2dq7X:31.60"],["4OTW_A_DB8A1101_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"LEU A 162;VAL A 170;LYS A 186;VAL A 220;LEU A 290;ALA A 319;ASP A 320","None","1.05A","4otwA-2eu9A:20.5","4otwA-2eu9A:22.67"],["4OTW_A_DB8A1101_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",10,"LEU A 273;VAL A 281;LYS A 295;VAL A 323;THR A 338;TYR A 340;GLY A 344;LEU A 393;ALA A 403;ASP A 404","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.7A);None;H8H A 534 (-3.1A);H8H A 534 (-4.3A);H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A);H8H A 534 (-4.2A)","0.54A","4otwA-2h8hA:33.5","4otwA-2h8hA:22.15"],["4OTW_A_DB8A1101_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;LYS A 295;VAL A 323;THR A 338;GLY A 344;LEU A 393;ALA A 403","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);None;None;QUE A   1 (-3.3A);QUE A   1 (-3.0A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.71A","4otwA-2hckA:31.0","4otwA-2hckA:25.55"],["4OTW_A_DB8A1101_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;LYS A 273;VAL A 301;THR A 316;GLY A 322;LEU A 371;ALA A 381","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.75A","4otwA-2hk5A:24.7","4otwA-2hk5A:31.60"],["4OTW_A_DB8A1101_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"LYS A 273;VAL A 301;THR A 316;GLY A 322;LEU A 371;ALA A 381;ASP A 382","1BM A 499 (-3.8A);None;1BM A 499 (-3.2A);1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A);1BM A 499 (-4.4A)","0.90A","4otwA-2hk5A:24.7","4otwA-2hk5A:31.60"],["4OTW_A_DB8A1101_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;LYS A 271;VAL A 299;THR A 315;GLY A 321;LEU A 370;ALA A 380","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.6A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.76A","4otwA-2hz0A:29.9","4otwA-2hz0A:36.33"],["4OTW_A_DB8A1101_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;VAL A 299;THR A 315;GLY A 321;LEU A 370;ALA A 380;ASP A 381","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);None;GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.76A","4otwA-2hz0A:29.9","4otwA-2hz0A:36.33"],["4OTW_A_DB8A1101_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",9,"LEU A 251;VAL A 259;LYS A 273;VAL A 301;THR A 316;TYR A 318;GLY A 322;LEU A 371;ALA A 381","None;None;1N8 A 501 ( 3.4A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.7A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A)","0.91A","4otwA-2og8A:28.3","4otwA-2og8A:32.10"],["4OTW_A_DB8A1101_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"LEU A 588;VAL A 596;VAL A 647;THR A 663;TYR A 665;GLY A 669;LEU A 785;VAL A 548","None","1.10A","4otwA-2ogvA:22.5","4otwA-2ogvA:29.65"],["4OTW_A_DB8A1101_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;LYS A 517;TYR A 566;GLY A 570;LEU A 633;ALA A 643","None","0.97A","4otwA-2psqA:29.1","4otwA-2psqA:28.40"],["4OTW_A_DB8A1101_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;LYS A 217;THR A 265;GLY A 271;LEU A 328;ALA A 338;ASP A 339","ADE A 488 ( 4.9A);None;ADE A 488 (-4.3A);ADE A 488 ( 4.1A);ADE A 488 (-4.4A);None;None","0.62A","4otwA-2qluA:24.3","4otwA-2qluA:24.79"],["4OTW_A_DB8A1101_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;VAL A 732;LYS A 751;VAL A 781;THR A 796;GLY A 802;LEU A 850;ASP A 861","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.9A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.0A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A);GW7 A   1 (-4.1A)","0.63A","4otwA-2r4bA:36.8","4otwA-2r4bA:56.23"],["4OTW_A_DB8A1101_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  90;LYS A 105;VAL A 137;TYR A 155;GLY A 159;LEU A 205;ALA A 215","None;ANP A1480 (-3.4A);ANP A1480 (-4.7A);ANP A1480 ( 4.9A);None;ANP A1480 ( 4.7A);ANP A1480 ( 4.1A)","0.90A","4otwA-2v55A:18.0","4otwA-2v55A:22.64"],["4OTW_A_DB8A1101_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",7,"LEU A  68;VAL A  76;LYS A  94;VAL A 125;GLY A 147;LEU A 194;ASP A 205","STU A   1 (-3.8A);None;STU A   1 (-2.8A);None;STU A   1 ( 3.9A);STU A   1 (-4.6A);STU A   1 ( 3.8A)","0.94A","4otwA-2z7rA:22.5","4otwA-2z7rA:25.00"],["4OTW_A_DB8A1101_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;VAL A 261;LYS A 275;VAL A 303;THR A 319;GLY A 325;LEU A 374;ALA A 384","None","0.75A","4otwA-2zv7A:28.8","4otwA-2zv7A:31.82"],["4OTW_A_DB8A1101_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;LYS A 517;TYR A 566;GLY A 570;LEU A 633;ALA A 643","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 ( 4.5A);M33 A1996 ( 4.7A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A);None","0.65A","4otwA-3b2tA:26.8","4otwA-3b2tA:30.75"],["4OTW_A_DB8A1101_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;TYR A 563;GLY A 567;LEU A 630;ALA A 640;ASP A 641","C4F A   1 ( 3.9A);None;None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A);C4F A   1 (-4.5A)","0.79A","4otwA-3c4fA:29.0","4otwA-3c4fA:29.26"],["4OTW_A_DB8A1101_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",8,"VAL A 209;LYS A 222;VAL A 249;THR A 266;TYR A 268;GLY A 272;LEU A 321;ASP A 332","None","0.87A","4otwA-3d7uA:25.6","4otwA-3d7uA:32.72"],["4OTW_A_DB8A1101_1","3fe3","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 3","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  70;LYS A  85;VAL A 116;TYR A 134;GLY A 138;LEU A 185;ALA A 195","None","1.03A","4otwA-3fe3A:18.9","4otwA-3fe3A:27.37"],["4OTW_A_DB8A1101_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 833;VAL A 841;LYS A 861;VAL A 892;TYR A 911;GLY A 915;LEU A1029","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 (-4.0A);8ST A2001 ( 4.7A);8ST A2001 (-4.9A);None;None","0.84A","4otwA-3hngA:28.2","4otwA-3hngA:26.97"],["4OTW_A_DB8A1101_1","3kex","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3","PF07714(Pkinase_Tyr)",12,"LEU A 696;VAL A 704;CYH A 721;LYS A 723;VAL A 753;THR A 768;TYR A 770;GLY A 774;LEU A 822;ALA A 832;ASP A 833;VAL A 836","ANP A   1 (-4.4A);ANP A   1 (-3.9A);ANP A   1 (-3.5A);ANP A   1 (-3.4A);None;ANP A   1 ( 4.8A);ANP A   1 (-4.3A);ANP A   1 ( 4.9A);ANP A   1 (-4.7A);None; MG A1001 ( 3.1A);None","0.49A","4otwA-3kexA:42.2","4otwA-3kexA:99.69"],["4OTW_A_DB8A1101_1","3mdy","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-1B","PF07714(Pkinase_Tyr);PF08515(TGF_beta_GS)",8,"VAL A 218;LYS A 231;THR A 279;TYR A 281;GLY A 285;LEU A 339;ALA A 349;ASP A 350","LDN A   1 ( 4.8A);None;LDN A   1 (-3.8A);LDN A   1 ( 4.8A);LDN A   1 (-3.3A);LDN A   1 (-4.5A);LDN A   1 ( 3.8A);LDN A   1 (-3.9A)","0.78A","4otwA-3mdyA:24.7","4otwA-3mdyA:24.06"],["4OTW_A_DB8A1101_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",8,"LEU A  49;VAL A  57;LYS A  72;VAL A 104;TYR A 122;GLY A 126;LEU A 173;ASP A 184","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);None;None;None;None;XFE A 351 (-4.6A);None","1.01A","4otwA-3mvjA:21.0","4otwA-3mvjA:23.80"],["4OTW_A_DB8A1101_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"LYS A 229;THR A 277;TYR A 279;GLY A 283;LEU A 337;ALA A 347;ASP A 348","LDN A 600 (-4.0A);LDN A 600 (-4.0A);LDN A 600 (-4.7A);LDN A 600 (-3.3A);LDN A 600 (-4.6A);LDN A 600 ( 3.8A);None","0.73A","4otwA-3my0A:24.6","4otwA-3my0A:27.43"],["4OTW_A_DB8A1101_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;LYS A 229;THR A 277;TYR A 279;GLY A 283;LEU A 337;ALA A 347","LDN A 600 (-4.5A);LDN A 600 (-4.0A);LDN A 600 (-4.0A);LDN A 600 (-4.7A);LDN A 600 (-3.3A);LDN A 600 (-4.6A);LDN A 600 ( 3.8A)","0.68A","4otwA-3my0A:24.6","4otwA-3my0A:27.43"],["4OTW_A_DB8A1101_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;VAL A 200;LYS A 215;VAL A 247;GLY A 269;LEU A 318;ASP A 329","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-2.8A);None;None;AMP A 577 (-4.8A);AMP A 577 (-4.0A)","0.86A","4otwA-3nyoA:20.5","4otwA-3nyoA:20.34"],["4OTW_A_DB8A1101_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",7,"LEU A 726;VAL A 734;LYS A 753;THR A 798;GLY A 804;LEU A 852;ASP A 863","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-4.7A);03Q A   1 (-4.1A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A);03Q A   1 (-4.0A)","0.82A","4otwA-3pp0A:35.3","4otwA-3pp0A:57.70"],["4OTW_A_DB8A1101_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"LYS A 578;VAL A 609;THR A 625;TYR A 627;GLY A 631;LEU A 683;ASP A 694","STU A   1 (-3.5A);None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A)","0.81A","4otwA-3ppzA:27.4","4otwA-3ppzA:31.40"],["4OTW_A_DB8A1101_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",7,"VAL A 565;VAL A 609;THR A 625;TYR A 627;GLY A 631;LEU A 683;ASP A 694","STU A   1 (-4.9A);None;STU A   1 (-4.1A);STU A   1 (-4.4A);STU A   1 (-3.2A);STU A   1 (-4.3A);STU A   1 (-3.5A)","0.61A","4otwA-3ppzA:27.4","4otwA-3ppzA:31.40"],["4OTW_A_DB8A1101_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"LEU A  63;VAL A  71;LYS A  86;THR A 144;GLY A 150;LEU A 197;ASP A 211","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.1A);ANP A1634 (-4.6A);None;ANP A1634 (-4.4A); MG A 529 (-2.2A)","1.09A","4otwA-3q5iA:19.9","4otwA-3q5iA:25.33"],["4OTW_A_DB8A1101_1","3s95","Homo sapiens","LIM DOMAIN KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 345;LYS A 368;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477","STU A   1 (-3.8A);STU A   1 (-3.1A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A)","0.79A","4otwA-3s95A:23.6","4otwA-3s95A:25.22"],["4OTW_A_DB8A1101_1","3s95","Homo sapiens","LIM DOMAIN KINASE 1","PF07714(Pkinase_Tyr)",7,"LEU A 345;THR A 413;TYR A 415;GLY A 419;LEU A 467;ALA A 477;ASP A 478","STU A   1 (-3.8A);STU A   1 (-3.9A);STU A   1 (-4.7A);STU A   1 (-3.6A);STU A   1 (-4.6A);STU A   1 ( 4.1A);STU A   1 ( 4.2A)","0.77A","4otwA-3s95A:23.6","4otwA-3s95A:25.22"],["4OTW_A_DB8A1101_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",8,"LEU A 423;VAL A 431;LYS A 445;VAL A 473;THR A 489;TYR A 491;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-4.5A);PP2 A   1 (-4.5A);None;PP2 A   1 (-3.3A);PP2 A   1 ( 4.9A);PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.62A","4otwA-3sxsA:29.4","4otwA-3sxsA:31.27"],["4OTW_A_DB8A1101_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;LYS A 514;TYR A 563;GLY A 567;LEU A 630;ALA A 640","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-4.5A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.84A","4otwA-3tt0A:28.8","4otwA-3tt0A:30.31"],["4OTW_A_DB8A1101_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;TYR A 563;GLY A 567;LEU A 630;ALA A 640;ASP A 641","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A);07J A   1 (-3.2A);07J A   1 (-4.7A)","0.77A","4otwA-3tt0A:28.8","4otwA-3tt0A:30.31"],["4OTW_A_DB8A1101_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",7,"LEU A 295;VAL A 303;LYS A 317;TYR A 365;GLY A 369;LEU A 423;ASP A 434","None","0.89A","4otwA-3ulzA:21.6","4otwA-3ulzA:26.97"],["4OTW_A_DB8A1101_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",7,"LEU A 139;VAL A 147;LYS A 162;TYR A 212;GLY A 216;LEU A 263;ALA A 273","N13 A 501 (-3.7A);N13 A 501 ( 4.7A);N13 A 501 (-2.9A);N13 A 501 (-4.4A);N13 A 501 (-3.5A);N13 A 501 (-4.5A);N13 A 501 ( 3.8A)","0.60A","4otwA-3w18A:22.3","4otwA-3w18A:23.89"],["4OTW_A_DB8A1101_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",7,"LEU A  83;VAL A  91;LYS A 106;TYR A 156;GLY A 160;LEU A 207;ALA A 217","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.3A);VX6 A 500 (-4.2A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A);VX6 A 500 ( 4.2A)","0.62A","4otwA-4af3A:19.3","4otwA-4af3A:23.01"],["4OTW_A_DB8A1101_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A  91;LYS A 106;TYR A 156;GLY A 160;LEU A 208;ALA A 218;ASP A 219","None;EDO A1419 (-3.3A);EDO A1420 (-4.9A);None;EDO A1420 ( 4.8A);None;None","0.71A","4otwA-4aw2A:19.4","4otwA-4aw2A:22.15"],["4OTW_A_DB8A1101_1","4c02","Homo sapiens","ACTIVIN RECEPTOR TYPE-1","PF00069(Pkinase);PF08515(TGF_beta_GS)",7,"VAL A 222;LYS A 235;THR A 283;TYR A 285;GLY A 289;LEU A 343;ALA A 353","TAK A1507 (-4.7A);TAK A1507 ( 4.5A);TAK A1507 (-3.6A);TAK A1507 ( 4.6A);TAK A1507 (-3.5A);TAK A1507 (-4.7A);TAK A1507 ( 4.2A)","0.61A","4otwA-4c02A:19.2","4otwA-4c02A:25.56"],["4OTW_A_DB8A1101_1","4cfh","Rattus norvegicus","5'-AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-1","PF00069(Pkinase);PF16579(AdenylateSensor)",8,"LEU A  22;VAL A  30;LYS A  45;TYR A  95;GLY A  99;LEU A 146;ALA A 156;ASP A 157","STU A1550 (-4.3A);None;STU A1550 (-3.6A);STU A1550 (-4.5A);STU A1550 (-3.4A);STU A1550 (-4.3A);STU A1550 ( 3.8A);STU A1550 (-3.6A)","0.99A","4otwA-4cfhA:22.4","4otwA-4cfhA:20.56"],["4OTW_A_DB8A1101_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",9,"LEU A 663;VAL A 671;LYS A 686;VAL A 721;TYR A 739;GLY A 743;LEU A 789;ALA A 799;ASP A 800","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.0A);None;None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A);AGS A1985 ( 3.3A)","0.91A","4otwA-4crsA:20.2","4otwA-4crsA:23.86"],["4OTW_A_DB8A1101_1","4eqm","Staphylococcus aureus","PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  16;VAL A  24;LYS A  39;VAL A  71;TYR A  89;LEU A 140;ASP A 151","ANP A 300 (-4.7A);ANP A 300 ( 4.7A);ANP A 300 (-3.1A);None;ANP A 300 (-4.3A);ANP A 300 (-4.7A);None","0.99A","4otwA-4eqmA:24.4","4otwA-4eqmA:23.08"],["4OTW_A_DB8A1101_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;LYS A 402;VAL A 433;GLY A 454;LEU A 501;ASP A 512","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.9A)","0.81A","4otwA-4f4pA:27.1","4otwA-4f4pA:32.34"],["4OTW_A_DB8A1101_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"LEU A 855;VAL A 863;LYS A 882;VAL A 911;GLY A 935;LEU A 983;ASP A 994","IZA A2001 (-3.7A);None;IZA A2001 ( 4.7A);None;IZA A2001 (-3.3A);IZA A2001 ( 4.7A);IZA A2001 ( 4.5A)","0.78A","4otwA-4gl9A:28.1","4otwA-4gl9A:28.74"],["4OTW_A_DB8A1101_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",7,"LEU A 855;VAL A 863;VAL A 911;TYR A 931;GLY A 935;LEU A 983;ASP A 994","IZA A2001 (-3.7A);None;None;None;IZA A2001 (-3.3A);IZA A2001 ( 4.7A);IZA A2001 ( 4.5A)","0.74A","4otwA-4gl9A:28.1","4otwA-4gl9A:28.74"],["4OTW_A_DB8A1101_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",8,"LEU A 828;VAL A 836;LYS A 855;VAL A 884;TYR A 904;GLY A 908;LEU A 956;ALA A 966","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.5A);None;19S A1201 (-4.7A);19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.77A","4otwA-4hviA:24.7","4otwA-4hviA:33.91"],["4OTW_A_DB8A1101_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",8,"LEU A 828;VAL A 836;VAL A 884;TYR A 904;GLY A 908;LEU A 956;ALA A 966;ASP A 967","19S A1201 (-3.9A);19S A1201 (-4.4A);None;19S A1201 (-4.7A);19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A);19S A1201 ( 4.1A)","0.83A","4otwA-4hviA:24.7","4otwA-4hviA:33.91"],["4OTW_A_DB8A1101_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",7,"LEU A 132;VAL A 140;LYS A 158;THR A 205;GLY A 211;LEU A 259;ASP A 270","None","0.75A","4otwA-4hzsA:24.9","4otwA-4hzsA:36.02"],["4OTW_A_DB8A1101_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",9,"LEU A 273;VAL A 281;LYS A 295;VAL A 323;TYR A 340;GLY A 344;LEU A 393;ALA A 403;ASP A 404","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 ( 4.7A);None;0J9 A 601 ( 4.7A);0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.5A);0J9 A 601 (-3.1A)","0.67A","4otwA-4k11A:33.3","4otwA-4k11A:25.00"],["4OTW_A_DB8A1101_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"LEU A 478;VAL A 486;LYS A 508;TYR A 557;GLY A 561;LEU A 624;ALA A 634;ASP A 635","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-2.7A);None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A);None; MG A 802 ( 3.0A)","0.89A","4otwA-4k33A:27.3","4otwA-4k33A:31.25"],["4OTW_A_DB8A1101_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",8,"LEU A  33;VAL A  41;LYS A  56;VAL A  83;TYR A 101;GLY A 105;LEU A 153;ALA A 163","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 403 ( 4.6A);GOL A 403 (-4.1A);GOL A 404 ( 4.9A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A);GOL A 403 ( 3.0A)","0.81A","4otwA-4lg4A:20.4","4otwA-4lg4A:27.33"],["4OTW_A_DB8A1101_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;LYS A 295;VAL A 323;TYR A 340;GLY A 344;LEU A 393;ALA A 403","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);VGG A 601 ( 4.0A);VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.2A)","0.83A","4otwA-4lggA:28.4","4otwA-4lggA:32.41"],["4OTW_A_DB8A1101_1","4m69","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"VAL A  36;LYS A  51;THR A  95;GLY A 101;LEU A 150;ALA A 160;ASP A 161","ANP A 401 (-4.5A);ANP A 401 (-2.9A);ANP A 401 (-3.8A);None;ANP A 401 (-4.8A);None; MG A 403 ( 3.1A)","0.64A","4otwA-4m69A:26.9","4otwA-4m69A:25.93"],["4OTW_A_DB8A1101_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;VAL A  54;LYS A  69;VAL A  99;THR A 123;GLY A 128;LEU A 180;ASP A 191","SIN A 401 ( 3.9A);None;None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.85A","4otwA-4o38A:18.4","4otwA-4o38A:22.80"],["4OTW_A_DB8A1101_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 595;VAL A 603;LYS A 642;THR A 687;TYR A 689;GLY A 693;LEU A 741","2TT A1201 (-4.1A);2TT A1201 (-4.2A);2TT A1201 ( 4.6A);None;2TT A1201 (-4.0A);2TT A1201 (-3.5A);2TT A1201 (-4.1A)","0.61A","4otwA-4oliA:27.9","4otwA-4oliA:21.80"],["4OTW_A_DB8A1101_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 627;VAL A 635;VAL A 685;TYR A 703;GLY A 707;LEU A 753;ALA A 763;ASP A 764","None","0.84A","4otwA-4otdA:16.8","4otwA-4otdA:25.63"],["4OTW_A_DB8A1101_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 386;VAL A 394;LYS A 409;TYR A 460;GLY A 464;LEU A 511;ALA A 521;ASP A 522","PZW A 801 (-3.9A);PZW A 801 (-4.6A);None;None;None;PZW A 801 (-4.8A);PZW A 801 ( 4.6A);PZW A 801 (-3.2A)","0.96A","4otwA-4q9zA:19.9","4otwA-4q9zA:25.72"],["4OTW_A_DB8A1101_1","4ra4","Homo sapiens","PROTEIN KINASE C","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 345;VAL A 353;LYS A 368;TYR A 419;GLY A 423;ALA A 480;ASP A 481","3KZ A 701 ( 4.1A);3KZ A 701 (-3.9A);3KZ A 701 ( 4.7A);None;None;3KZ A 701 ( 4.8A);3KZ A 701 (-2.9A)","1.10A","4otwA-4ra4A:20.1","4otwA-4ra4A:27.18"],["4OTW_A_DB8A1101_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",9,"LEU A  14;VAL A  22;LYS A  37;VAL A  65;THR A  81;TYR A  83;GLY A  87;LEU A 136;ALA A 146","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);None;None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None","0.67A","4otwA-4ueuA:28.5","4otwA-4ueuA:33.33"],["4OTW_A_DB8A1101_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  65;THR A  81;TYR A  83;GLY A  87;LEU A 136;ALA A 146;ASP A 147","None;ACP A1264 (-4.5A);ACP A1264 ( 4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None;None","0.92A","4otwA-4ueuA:28.5","4otwA-4ueuA:33.33"],["4OTW_A_DB8A1101_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  40;VAL A  48;LYS A  63;VAL A  92;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-4.5A);None;6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.81A","4otwA-4usfA:17.3","4otwA-4usfA:27.13"],["4OTW_A_DB8A1101_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",8,"LEU A 104;VAL A 112;LYS A 127;VAL A 159;TYR A 177;GLY A 181;LEU A 228;ASP A 239","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-2.6A);None;None;None;ATP A 501 (-4.5A); ZN A 503 (-1.9A)","1.01A","4otwA-4wb7A:21.1","4otwA-4wb7A:22.14"],["4OTW_A_DB8A1101_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;LYS A 216;VAL A 248;GLY A 270;LEU A 321;ASP A 332","ANW A 601 ( 4.0A);None;None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A);None","0.92A","4otwA-4wboA:21.0","4otwA-4wboA:20.45"],["4OTW_A_DB8A1101_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",8,"LEU B 267;VAL B 275;LYS B 290;VAL B 318;THR B 334;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.55A","4otwA-4xeyB:25.7","4otwA-4xeyB:27.65"],["4OTW_A_DB8A1101_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","None","1.02A","4otwA-4xi2A:28.0","4otwA-4xi2A:22.06"],["4OTW_A_DB8A1101_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"LEU A 616;VAL A 624;LYS A 644;VAL A 675;TYR A 693;GLY A 697;LEU A 818","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 ( 4.0A);None;P30 A1001 ( 4.4A);P30 A1001 (-3.5A);P30 A1001 (-4.3A)","0.88A","4otwA-4xufA:23.3","4otwA-4xufA:31.99"],["4OTW_A_DB8A1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;LYS A 430;VAL A 458;TYR A 476;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-3.7A);None;746 A 702 (-4.4A);746 A 702 (-3.6A);746 A 702 (-4.4A)","0.91A","4otwA-4y93A:31.1","4otwA-4y93A:20.56"],["4OTW_A_DB8A1101_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",7,"LEU A 408;VAL A 416;VAL A 458;THR A 474;TYR A 476;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);None;746 A 702 (-3.7A);746 A 702 (-4.4A);746 A 702 (-3.6A);746 A 702 (-4.4A)","0.66A","4otwA-4y93A:31.1","4otwA-4y93A:20.56"],["4OTW_A_DB8A1101_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;LYS A 490;THR A 539;TYR A 541;LEU A 595;ALA A 605;ASP A 606","None;4CV A 801 (-3.9A);4CV A 801 (-2.8A);4CV A 801 (-3.9A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A);4CV A 801 (-3.5A)","0.96A","4otwA-4yffA:24.7","4otwA-4yffA:28.85"],["4OTW_A_DB8A1101_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;THR A 539;TYR A 541;GLY A 545;LEU A 595;ALA A 605;ASP A 606","None;4CV A 801 (-2.8A);4CV A 801 (-3.9A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A);4CV A 801 (-3.5A)","0.68A","4otwA-4yffA:24.7","4otwA-4yffA:28.85"],["4OTW_A_DB8A1101_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;LYS A 514;TYR A 563;GLY A 567;LEU A 630;ALA A 640;ASP A 641","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 ( 3.1A);38O A1769 (-4.2A);38O A1769 (-3.4A);38O A1769 (-4.6A);EDO A1766 ( 4.4A);38O A1769 (-4.0A)","0.86A","4otwA-5a46A:28.9","4otwA-5a46A:30.15"],["4OTW_A_DB8A1101_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",8,"VAL A  70;LYS A  85;VAL A 116;TYR A 134;GLY A 138;LEU A 185;ALA A 195;ASP A 196","5RC A4000 (-4.6A);5RC A4000 (-2.8A);None;5RC A4000 (-4.5A);5RC A4000 (-3.3A);None;5RC A4000 ( 3.9A);5RC A4000 (-3.6A)","1.01A","4otwA-5es1A:21.8","4otwA-5es1A:26.07"],["4OTW_A_DB8A1101_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;LYS A 930;TYR A 980;GLY A 984;LEU A1030;ASP A1041","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);None;5U3 A1200 (-4.5A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A);5U3 A1200 ( 4.9A)","0.78A","4otwA-5f1zA:28.8","4otwA-5f1zA:32.28"],["4OTW_A_DB8A1101_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",7,"LEU A 599;VAL A 607;LYS A 627;THR A 674;TYR A 676;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-4.0A);748 A1001 (-3.2A);748 A1001 (-4.0A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.71A","4otwA-5grnA:24.0","4otwA-5grnA:30.77"],["4OTW_A_DB8A1101_1","5gza","Danio rerio","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",7,"VAL A  93;VAL A 133;THR A 147;TYR A 149;GLY A 153;LEU A 214;ASP A 225","ADP A 401 (-4.4A);None;ADP A 401 ( 4.8A);ADP A 401 ( 4.8A);ADP A 401 ( 4.1A);ADP A 401 (-4.4A); MG A 402 ( 1.8A)","0.91A","4otwA-5gzaA:17.2","4otwA-5gzaA:24.14"],["4OTW_A_DB8A1101_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",8,"LEU A  20;VAL A  28;LYS A  43;VAL A  74;GLY A  96;LEU A 143;ALA A 156;ASP A 157","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-2.7A);None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A); MG A 302 ( 3.3A)","1.03A","4otwA-5hu3A:23.0","4otwA-5hu3A:24.63"],["4OTW_A_DB8A1101_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A  57;VAL A  65;VAL A 109;TYR A 132;GLY A 136;LEU A 187;ASP A 198","IDV A 401 (-3.8A);IDV A 401 (-4.6A);None;IDV A 401 (-3.5A);IDV A 401 (-3.4A);IDV A 401 (-4.4A);IDV A 401 (-4.0A)","0.63A","4otwA-5i3oA:16.3","4otwA-5i3oA:23.81"],["4OTW_A_DB8A1101_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",7,"VAL A  30;LYS A  45;VAL A  74;GLY A  96;LEU A 143;ALA A 153;ASP A 154","6G2 A 901 ( 4.9A);6G2 A 901 ( 3.9A);None;6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A);6G2 A 901 (-3.4A)","0.76A","4otwA-5j5tA:21.2","4otwA-5j5tA:26.41"],["4OTW_A_DB8A1101_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",8,"VAL A 106;LYS A 121;VAL A 153;TYR A 171;GLY A 175;LEU A 221;ALA A 231;ASP A 232","None","0.93A","4otwA-5u7qA:18.7","4otwA-5u7qA:23.90"],["4OTW_A_DB8A1101_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",8,"LEU A  24;VAL A  32;LYS A  47;THR A  95;TYR A  97;GLY A 101;LEU A 153;ALA A 163","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);9WS A 401 (-3.2A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A);9WS A 401 ( 4.0A)","0.56A","4otwA-5w5jA:24.2","4otwA-5w5jA:26.72"],["4OTW_A_DB8A1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"LEU A 891;VAL A 899;LYS A 919;THR A 963;TYR A 965;GLY A 969;LEU A1017","ANP A1201 (-4.1A);ANP A1201 (-4.4A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A)","0.54A","4otwA-5wnoA:34.6","4otwA-5wnoA:17.60"],["4OTW_A_DB8A1101_1","5wno","Caenorhabditis elegans","RECEPTOR TYROSINE-PROTEIN KINASE LET-23","no annotation",7,"VAL A 899;LYS A 919;THR A 963;TYR A 965;GLY A 969;LEU A1017;ASP A1028","ANP A1201 (-4.4A);ANP A1201 (-3.8A);ANP A1201 (-3.9A);ANP A1201 (-4.4A);ANP A1201 ( 4.6A);ANP A1201 (-4.7A); MG A1202 ( 3.0A)","0.73A","4otwA-5wnoA:34.6","4otwA-5wnoA:17.60"],["4OTW_A_DB8A1101_1","5xd6","Arabidopsis thaliana","PROTEIN KINASE SUPERFAMILY PROTEIN","no annotation",7,"VAL A  83;LYS A  97;VAL A 125;TYR A 143;GLY A 147;LEU A 206;ALA A 216","ANP A1000 (-4.1A);ANP A1000 (-2.8A);None;ANP A1000 (-4.3A);None;ANP A1000 (-4.5A); MG A1001 ( 4.4A)","0.58A","4otwA-5xd6A:23.9","4otwA-5xd6A:13.74"],["4OTW_A_DB8A1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"LEU A  33;VAL A  41;LYS A  56;TYR A 101;ALA A 163;ASP A 164;VAL A 167","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 (-2.4A);ANP A 501 ( 4.2A);None; MG A 502 ( 3.1A);None","0.83A","4otwA-6ao5A:23.4","4otwA-6ao5A:26.36"],["4OTW_A_DB8A1101_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",9,"LEU A  33;VAL A  41;LYS A  56;VAL A  83;TYR A 101;GLY A 105;LEU A 153;ALA A 163;VAL A 167","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.2A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A);None;None","0.69A","4otwA-6ao5A:23.4","4otwA-6ao5A:26.36"],["4OTW_A_DB8A1101_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;LYS A 908;VAL A 938;GLY A 962;LEU A1010;ASP A1021","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-2.8A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A); MG A1203 (-1.8A)","0.95A","4otwA-6c7yA:28.5","4otwA-6c7yA:13.72"],["4OTW_A_DB8A1101_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",7,"VAL A  74;LYS A  89;VAL A 120;TYR A 138;LEU A 189;ALA A 199;ASP A 200","None","1.04A","4otwA-6c9dA:21.1","4otwA-6c9dA:13.04"],["4OTW_A_DB8A1101_1","6c9d","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK1,SERINE\/THREONINE-PROTEIN KINASE MARK1","no annotation",7,"VAL A  74;VAL A 120;TYR A 138;GLY A 142;LEU A 189;ALA A 199;ASP A 200","None","0.88A","4otwA-6c9dA:21.1","4otwA-6c9dA:13.04"],["4OTW_A_DB8A1101_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",7,"VAL A 142;LYS A 157;VAL A 212;GLY A 236;LEU A 282;ALA A 292;ASP A 293","H1N A 501 (-4.4A);H1N A 501 (-2.8A);H1N A 501 (-4.9A);H1N A 501 (-3.6A);H1N A 501 (-4.8A);H1N A 501 ( 3.9A);H1N A 501 (-3.5A)","0.77A","4otwA-6ccfA:23.1","4otwA-6ccfA:18.22"],["4OTW_A_DB8A1101_1","6fdy","-","-","no annotation",7,"LEU U  20;LYS U  44;VAL U  75;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.80A","4otwA-6fdyU:20.6","4otwA-6fdyU:undetectable"],["4OTW_A_DB8A1101_1","6fdy","-","-","no annotation",7,"LEU U  20;VAL U  28;LYS U  44;VAL U  75;GLY U  97;LEU U 144;ALA U 156","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 ( 4.0A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A)","0.73A","4otwA-6fdyU:20.6","4otwA-6fdyU:undetectable"]]